Splicing profile by capture RNA-seq identifies pathogenic germline variants in tumor suppressor genes
-
Published:2020-02-24
Issue:1
Volume:4
Page:
-
ISSN:2397-768X
-
Container-title:npj Precision Oncology
-
language:en
-
Short-container-title:npj Precis. Onc.
Author:
Landrith Tyler, Li Bing, Cass Ashley A., Conner Blair R.ORCID, LaDuca Holly, McKenna Danielle B., Maxwell Kara N., Domchek SusanORCID, Morman Nichole A.ORCID, Heinlen Christopher, Wham Deborah, Koptiuch Cathryn, Vagher Jennie, Rivera Ragene, Bunnell Ann, Patel Gayle, Geurts Jennifer L., Depas Morgan M., Gaonkar Shraddha, Pirzadeh-Miller Sara, Krukenberg RebekahORCID, Seidel Meredith, Pilarski Robert, Farmer Meagan, Pyrtel Khateriaa, Milliron Kara, Lee JohnORCID, Hoodfar Elizabeth, Nathan Deepika, Ganzak Amanda C., Wu SitaoORCID, Vuong Huy, Xu Dong, Arulmoli Aarani, Parra Melissa, Hoang Lily, Molparia Bhuvan, Fennessy Michele, Fox Susanne, Charpentier Sinead, Burdette JuliaORCID, Pesaran TinaORCID, Profato Jessica, Smith Brandon, Haynes Ginger, Dalton Emily, Crandall Joy Rae-Radecki, Baxter Ruth, Lu Hsiao-Mei, Tippin-Davis Brigette, Elliott Aaron, Chao Elizabeth, Karam RachidORCID
Abstract
AbstractGermline variants in tumor suppressor genes (TSGs) can result in RNA mis-splicing and predisposition to cancer. However, identification of variants that impact splicing remains a challenge, contributing to a substantial proportion of patients with suspected hereditary cancer syndromes remaining without a molecular diagnosis. To address this, we used capture RNA-sequencing (RNA-seq) to generate a splicing profile of 18 TSGs (APC, ATM, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, MLH1, MSH2, MSH6, MUTYH, NF1, PALB2, PMS2, PTEN, RAD51C, RAD51D, and TP53) in 345 whole-blood samples from healthy donors. We subsequently demonstrated that this approach can detect mis-splicing by comparing splicing profiles from the control dataset to profiles generated from whole blood of individuals previously identified with pathogenic germline splicing variants in these genes. To assess the utility of our TSG splicing profile to prospectively identify pathogenic splicing variants, we performed concurrent capture DNA and RNA-seq in a cohort of 1000 patients with suspected hereditary cancer syndromes. This approach improved the diagnostic yield in this cohort, resulting in a 9.1% relative increase in the detection of pathogenic variants, demonstrating the utility of performing simultaneous DNA and RNA genetic testing in a clinical context.
Publisher
Springer Science and Business Media LLC
Subject
Computer Science Applications,History,Education
Reference45 articles.
1. Rivas, M. A. et al. Human genomics. Effect of predicted protein-truncating genetic variants on the human transcriptome. Science 348, 666–669 (2015). 2. Scotti, M. M. & Swanson, M. S. RNA mis-splicing in disease. Nat. Rev. Genet. 17, 19–32 (2016). 3. Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405–424 (2015). 4. Park, E., Pan, Z., Zhang, Z., Lin, L. & Xing, Y. The expanding landscape of alternative splicing variation in human populations. Am. J. Hum. Genet. 102, 11–26 (2018). 5. Cummings, B. B. et al. Improving genetic diagnosis in Mendelian disease with transcriptome sequencing. Sci. Transl. Med. 9, https://doi.org/10.1126/scitranslmed.aal5209 (2017).
Cited by
48 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|